Barbara Schacher Engstler

Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang et al. · Clinical Cancer Research · 2019 · 173 citations

Medicine, Oncology, Pharmacology +17

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia

Caroline Dafflon, Vanessa J. Craig, Hélène Méreau et al. · Leukemia · 2016 · 109 citations

Medicine, Molecular Biology, Oncology +5

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Sunkyu Kim, Ralph Tiedt, Alice Loo et al. · Oncotarget · 2018 · 93 citations · Full text

Medicine, Oncology, Pharmacology +14

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway

Caroline Dafflon, Swann Gaulis, Louise Barys et al. · Oncotarget · 2020 · 16 citations · Full text

Medicine, Molecular Biology, Oncology +12

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

Ralph Tiedt, Frederick J. King, Christelle Stamm et al. · Cell Reports · 2023 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17